Royal Bank of Canada’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.03M | Buy |
401,121
+132,108
| +49% | +$668K | ﹤0.01% | 3011 |
|
|
2025
Q1 | $1.42M | Buy |
269,013
+232,038
| +628% | +$1.23M | ﹤0.01% | 2902 |
|
|
2024
Q4 | $250K | Sell |
36,975
-8,357
| -18% | -$56.5K | ﹤0.01% | 4181 |
|
|
2024
Q3 | $299K | Sell |
45,332
-4,403
| -9% | -$29K | ﹤0.01% | 4084 |
|
|
2024
Q2 | $373K | Buy |
49,735
+34,126
| +219% | +$256K | ﹤0.01% | 3878 |
|
|
2024
Q1 | $155K | Sell |
15,609
-18,456
| -54% | -$183K | ﹤0.01% | 4468 |
|
|
2023
Q4 | $336K | Buy |
34,065
+7,900
| +30% | +$77.9K | ﹤0.01% | 4119 |
|
|
2023
Q3 | $200K | Buy |
26,165
+11,676
| +81% | +$89.2K | ﹤0.01% | 4329 |
|
|
2023
Q2 | $108K | Buy |
14,489
+6,581
| +83% | +$49.1K | ﹤0.01% | 4836 |
|
|
2023
Q1 | $53K | Sell |
7,908
-14,501
| -65% | -$97.2K | ﹤0.01% | 5213 |
|
|
2022
Q4 | $172K | Buy |
22,409
+20,462
| +1,051% | +$157K | ﹤0.01% | 4547 |
|
|
2022
Q3 | $21K | Buy |
1,947
+935
| +92% | +$10.1K | ﹤0.01% | 5627 |
|
|
2022
Q2 | $8K | Sell |
1,012
-6,069
| -86% | -$48K | ﹤0.01% | 6012 |
|
|
2022
Q1 | $51K | Sell |
7,081
-17,722
| -71% | -$128K | ﹤0.01% | 5601 |
|
|
2021
Q4 | $425K | Buy |
24,803
+21,954
| +771% | +$376K | ﹤0.01% | 4117 |
|
|
2021
Q3 | $65K | Buy |
2,849
+1,404
| +97% | +$32K | ﹤0.01% | 5483 |
|
|
2021
Q2 | $53K | Buy |
+1,445
| New | +$53K | ﹤0.01% | 5509 |
|